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clinical and demographic differences between patients,
and to better understand deﬁnitively the value of new
treatments.
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DEVELOPMENT OF A PREFERENCE
ELICITATION INSTRUMENT FOR USE IN
PATIENTS WITH NEWLY DIAGNOSED BRAIN
METASTASES IN A PROSPECTIVE RANDOMIZED
CLINICAL TRIAL
Adamus AT, Chang EL, Arbuckle R, King K
The University of Texas M.D. Anderson Cancer Center,
Houston,TX, USA
OBJECTIVE: The prevalence of brain metastases in
cancer patients is 20–40% and treatment options offer
median survivals of 4–10 months. Comparing two treat-
ments that do not offer increases in survival in a disease
state with a small survival rate lends itself to the study of
patient preferences. Patients are left to choose between
the risk of recurrent metastatic disease or the physical 
and cognitive side effects associated with treatment. The
objective of this study was to assess the feasibility of the
time trade-off method in patients with brain metastases
participating in a clinical trial. METHODS: An instru-
ment was developed for patients with brain metastases
undergoing radiosurgery with and without whole brain
radiation. Research nurses were trained to administer the
instrument face-to-face during clinic visits. RESULTS:
The instrument included a written script, data collection
form, and visual aid to facilitate the understanding of
trading time. Patients traded time for 3 different time
periods—10 years, 5 years, and one year. The piloted
instrument resulted in two changes: 1) the visual aid was
eliminated because it did not add to patients understand-
ing of trading time, and 2) the concept of “optimal
health” was used instead of “perfect health” because
patients had difﬁculty with the term. Currently, the
instrument has been administered to 25 patients. Fifty-six
percent, 44%, and 36% of patients traded time in the 10-
year, 5-year, and 1-year time period respectively. Three
patients from each time period increased the time that
they would trade during the course of treatment from
baseline. CONCLUSIONS: Methods used to elicit pref-
erences must be balanced with the practical issues of clin-
ical practice to yield clinically useful options to be used
by clinicians and patients for decision-making. 
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MEDICATION COMBINATION PRESCRIPTION
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Balkrishnan R, Cook JM, Feldman SR, Fleischer Jr AB
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NC, USA
OBJECTIVE: Despite concerns associated with the 
necessity of an additional ﬂuorinated, high potency
topical corticosteroid, the clotrimazole/betamethasone
diproprionate combination remains a frequently pre-
scribed topical agent in the U.S. This research was per-
formed to better understand the circumstances in which
physicians across specialties in the U.S. recommend the
use of the combination medication in outpatient settings.
Additionally, the study aimed to determine the diagnoses
and characteristics of patients for whom the combination
medication was prescribed. METHODS: Data from the
National Ambulatory Medical Care Survey (1990-2000)
were used to determine the demographic characteristics
of patients with dermatologic diagnoses who were given
a prescription for clotrimazole/betamethasone dipropri-
onate. The most common diagnoses of patients treated
with the drug were also determined. RESULTS: Family
medicine physicians were more than twice as likely (OR:
2.61, 95% CI: 1.59, 4.30) and internists were more than
3 times as likely (OR: 3.52, 95% CI: 2.07, 5.97) 
to prescribe clotrimazole/betamethasone diproprionate
compared to all other physicians when faced with a der-
matologic diagnosis. Prescription rates of the combina-
tion medication were higher among patients of 
non-white race (OR: 1.55, CI: 1.07, 2.25). Contact 
dermatitis and other eczema ranked highest among 
diagnoses associated with the combination medication
mention by family medicine physicians, internists, and
pediatricians. CONCLUSIONS: The frequent use of
clotrimazole/betamethasone diproprionate by primary
care physicians is of concern. Use of alternative agents
with anti-inﬂammatory and antifungal properties without
the associated risks of high potency topical corticos-
teroids would be a preferable alternative.




BIMATOPROST VERSUS LATANOPROST 
PLUS ADJUNCTIVE PRODUCTS FOR
GLAUCOMA TREATMENT
Walt JH1, Spalding JR2, Habib L3
1Allergan, Irvine, CA, USA; 2University of Southern California,
Los Angeles, CA, USA; 3Keck Graduate Institute, Claremont,
CA, USA
OBJECTIVES: Prostamides have recently been intro-
duced to treat glaucoma patients. We evaluated the effec-
tiveness and pharmacoeconomic impact of these newer
medications in treating patients with glaucoma. We com-
pared effectiveness and costs of bimatoprost monother-
apy versus latanoprost used with adjunctive therapies.
METHODS: A pharmacoeconomic model was con-
structed based on a two-month naturalistic effectiveness
trial comparing bimatoprost 0.03% (AWP of $53.13) in
patients switched from all possible combination therapies
with latanoprost 0.005% (AWP weighted total average
